UNC Lineberger Comprehensive Cancer Center’s Multiple Myeloma & Amyloidosis Program treats multiple myeloma, amyloidosis and other plasma cell-related disorders such as solitary plasmacytoma, POEMS syndrome, monoclonal gammopathy of uncertain significance (MGUS), asymptomatic “smoldering” myeloma and Castleman’s disease.
UNC’s Multiple Myeloma & Amyloidosis Program offers patients and referring physicians access to a complete range of both diagnostic and therapeutic services for multiple myeloma and other plasma cell disorders. These include chemotherapy, radiation therapy and stem cell transplantation. Multiple specialists are part of our team, helping you manage side effects and symptoms of your condition and treatment side effects.
Multiple myeloma and other plasma cell disorders are problems of plasma cells, and in fact some, such as multiple myeloma, are a true cancer of the plasma cells. Plasma cells are found in bone marrow, which is the space inside bones where blood is made. In multiple myeloma and other plasma cell disorders, abnormal plasma cells grow in the bone marrow. Those plasma cells also usually produce an abnormal protein (often called a monoclonal protein, M-protein, M-spike, or “light chains”). The plasma cells and/or the abnormal protein can cause damage.
Due to the complicated nature of these disorders, our multidisciplinary approach, with input from experts from a number of specialties, allows us to excel in treating these patients. We ensure that expertly developed care is individualized for each patient and delivered in a well-coordinated and caring manner by incorporating specialists from hematology, medical, radiation oncology, pathology, UNC Imaging and Spine Center, the Bone Marrow Transplant and Cellular Therapy Program, radiology, and oncology nursing into a single patient care team.
The following is a list of myeloma clinical trials at this center.
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
The following is a listing of clinical trials for patients with Smoldering Myeloma.
The following is a listing of clinical trials for patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).
A cancer diagnosis can affect so many parts of our lives, including finances. We all know that even without cancer finances can cause stress in our lives. Many people have unplanned expenses related to their care. UNC Lineberger offers a wide range of options for patients.
SparkCures is working closely with UNC Lineberger Comprehensive Cancer Center University of North Carolina to provide the most up-to-date information on their myeloma program, specialists and clinical trials. Use the buttons above to claim this as your Home Center or add it to your List of Favorites.
Learn more about how we work with myeloma centers